The study by Patel et al. [6] reported unfavorable overall outcomes in their cohort of NPM1-mutated myeloid neoplasms (including CMML and MDS), with the majority of patients undergoing initial HMA therapy. This evidence concerns the gene NPM1 and myeloid neoplasm.